Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
L-756423 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| L-756423 | DRUG | - |
| Indinavir sulfate | DRUG | - |
Inclusion Criteria You may be eligible for this study if you: * Are HIV-positive. * Are at least 18 years old. * Have a viral load of at least 1,000 copies/ml. * Have a CD4 cell count of at least 100 cells/mm3. * Have experienced treatment failure (your viral load increased significantly) within 2...
Top 20 of 28 competitors
L-756423 is an investigational small molecule being studied for the treatment of HIV infections. It was evaluated in a Phase 2 clinical trial in combination with indinavir in HIV-positive patients who had previously taken indinavir. The drug is not approved and remains in clinical development.
L-756423 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company conducted a Phase 2 clinical trial of the drug for HIV infections.
L-756423 is in Phase 2 clinical development. It has completed one Phase 2 trial, and no active trials are currently listed. The drug is investigational and has not been approved by regulatory authorities.
L-756423 has been studied in one completed Phase 2 trial, NCT00002452, titled "A Study on the Safety and Effectiveness of L-756423 Plus Indinavir in HIV-Positive Patients Who Have Previously Taken Indinavir." The trial enrolled 30 participants in the United States.
No, L-756423 is not the same as indinavir. In the clinical trial NCT00002452, L-756423 was studied in combination with indinavir, meaning they are separate drugs. The trial evaluated the safety and effectiveness of adding L-756423 to indinavir in HIV-positive patients.